Home
RAPP
RAPP News

Latest Rapport Therapeutics Inc. Common Stock (RAPP) News on November 24, 2024

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

GlobeNewswire

10 days ago

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

Rapport Therapeutics expects cash to fund requirements through 2026

TipRanks

16 days ago

Rapport Therapeutics expects cash to fund requirements through 2026

Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update

GlobeNewswire

17 days ago

Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

GlobeNewswire

20 days ago

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

GlobeNewswire

3 months ago

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit

GlobeNewswire

3 months ago

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update

GlobeNewswire

4 months ago

Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain

GlobeNewswire

4 months ago

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

GlobeNewswire

5 months ago

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

Share on Social Networks: